Research on platelet AR activity supports targeting AR signaling as an attractive strategy to prevent platelet hyperactivation (“hypersensitive” phenotype) and inhibit thrombosis, and preserve physiological hemostasis in T2DM (10, 12). This evidence concerns the gene AR and type 2 diabetes mellitus.